^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

880P - Phase II trial of the cyclin dependent kinase 4/6 inhibitor SHR6390 in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification

Published date:
09/05/2022
Excerpt:
We performed a phase II study to determine the efficiency and safety of SHR6390, a CDK4/6 inhibitor, in pts with HNMM harboring CDK4 amplification….This study showed that SHR6390 was well-tolerated and appeared to be effective in HNMM pts harboring CDK4 amplification, which hints that it's worthy to further explore SHR6390 in combination with other drugs in the systemic treatment of advanced MM.